- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Biospecimen Collection, Chest Computed Tomography, Echocardiography, Hematopoietic Cell Transplantation, Methotrexate, Multigated Acquisition Scan, Ruxolitinib Phosphate, Tacrolimus
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 2 Years to 22 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 2,698
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Allergy, Allergic Asthma, Allergy to Cats, Allergy to House Dust, Allergy to Dog Dander (Finding), Allergy Mold, Allergy Cockroach
- Interventions
- Blood Collection
- Device
- Lead sponsor
- Abionic SA
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Cincinnati, Ohio
- Conditions
- Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
- Interventions
- Biospecimen Collection, Computed Tomography, Mosunetuzumab, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 286
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 228 more
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib
- Procedure · Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Minutes and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 278
- States / cities
- Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 232 more
- Conditions
- Glioma, Malignant Glioma, Recurrent Glioma, Recurrent Malignant Glioma
- Interventions
- Biospecimen Collection, Diagnostic Imaging, Magnetic Resonance Imaging
- Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hematologic Malignancy
- Interventions
- Blood and/or platelet transfusion, Complete blood count (CBC) collection
- Procedure
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Anesthesia
- Interventions
- Final exogenous oxytocin concentration=22.5 μU/mL, Final exogenous oxytocin concentration=30.1μU/mL, Final exogenous oxytocin concentration=32.9μU/mL
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Vehicular Environment
- Interventions
- HEPA air purifier, questionnaires, Log-book, Urine sample
- Device · Behavioral · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years to 90 Years · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Fluorouracil, Gemcitabine, Irinotecan, Irinotecan Sucrosofate, Leucovorin, Nab-paclitaxel, Panitumumab, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 274
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 207 more
- Conditions
- HIV
- Interventions
- Standard of Care, FemAALES
- Behavioral
- Lead sponsor
- Charles Drew University of Medicine and Science
- Other
- Eligibility
- 18 Years to 54 Years · Female only
- Enrollment
- 256 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Navtemadlin, Radiation Therapy
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 6 more
- Conditions
- Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
- Interventions
- Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 409
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy, Flotufolastat F-18, Lutetium Lu 177 PSMA-10.1, Positron Emission Tomography, Single Photon Emission Computed Tomography
- Procedure · Radiation · Other + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery, Milestone 3: Chemoradiotherapy (cXRT), Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery, Milestone 4: Chemoradiotherapy (cXRT), Milestone 5: Targeted chemotherapy after surgery, Milestone 5: Chemoradiotherapy (cXRT), Milestone 6: Gemcitabine after surgery, Milestone 6: Chemoradiotherapy (cXRT), Milestone 7: Chemoradiotherapy (cXRT), Milestone 8: Targeted chemotherapy after surgery, Milestone 9: Gemcitabine after surgery, Milestone 10: No additional therapy after surgery
- Drug · Radiation · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Milwaukee, Wisconsin
- Conditions
- Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
- Interventions
- Endocrine Therapy, Biopsy of breast, Neratinib, Biospecimen Collection, Mammogram, Magnetic Resonance Imaging, Breast Surgery, Ultrasound
- Procedure · Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Pittsburgh, Pennsylvania • Nashville, Tennessee + 2 more
- Conditions
- Malignant Digestive System Neoplasm
- Interventions
- Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride, Electrocardiogram, Fluorouracil, Holter Monitoring, Isosorbide Mononitrate, Medical Device Usage and Evaluation, Placebo Administration, Questionnaire Administration
- Procedure · Drug · Device + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Recurrent Melanoma, Stage IV Melanoma
- Interventions
- temozolomide, flow cytometry, staining method, biopsy, laboratory biomarker analysis
- Drug · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Head and Neck Cancers
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 1,468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
- Interventions
- Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review
- Procedure · Drug · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 3
- States / cities
- San Francisco, California • The Bronx, New York • Durham, North Carolina
- Conditions
- Esophageal Cancer
- Interventions
- Chemotherapy, Radiation Therapy, Surgery, MRI Imaging, Blood Draws
- Radiation · Procedure · Device + 1 more
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL
- Interventions
- Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy, CT Scans, 18F-FDG-PET/CT Scan15, Electrocardigram
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Dental Caries
- Interventions
- 0.425 % w/w phytate,1150ppm F, 0.85 % w/w phytate,1150ppm F, 0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F, 0 ppm F, 1150ppm F, 0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Iberdomide, Magnetic Resonance Imaging, Patient Monitoring, Positron Emission Tomography, Skeletal Survey X-Ray
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 74
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 55 more
- Conditions
- Kidney Transplant; Complications, Obesity
- Interventions
- Education regarding Weight loss, Lifestyle tools for weight loss, Blood draw
- Behavioral · Biological
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Richmond, Virginia